Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Senti Biosciences (SNTI) presented promising preclinical data on its SENTI-202 CAR-NK cell therapy at the AACR Annual Meeting. This therapy targets CD33 and/or FLT3 for treating hematologic malignancies, showing enhanced cytotoxic activity and safety in in vitro and in vivo models. The company aims to submit an IND application by the second half of 2023, focusing on relapsed/refractory patients. Data on SENTI-301A further demonstrated CAR-NK cells' ability to improve persistence and anti-tumor efficacy. Overall, Senti Bio aims to revolutionize treatment for both liquid and solid tumors through its innovative gene circuit technology.
Senti Biosciences, Inc. (Nasdaq: SNTI), a biotechnology innovator in cell and gene therapies, announced its participation in several upcoming investor conferences. The events include:
- Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Date: April 24, 2023, 10:00 a.m. ET (Virtual) - Bank of America 2023 Global Healthcare Conference
Date: May 10, 2023 (Las Vegas, NV) - The JMP Securities Life Sciences Conference
Date: May 15, 2023, 2:30 p.m. ET (New York, NY)
Live webcasts will be available via the Senti Bio website, with archived replays accessible for 90 days after each event. Senti Bio aims to pioneer smarter therapies through its synthetic biology platform and proprietary Gene Circuit technology to enhance treatment precision in complex diseases.
Senti Biosciences (SNTI) reported significant advancements in its therapeutic pipeline, particularly with the upcoming IND application for SENTI-202 aimed at treating hematologic malignancies including AML and MDS, scheduled for submission in H2 2023. The company holds $98.6 million in cash and equivalents as of December 31, 2022, ensuring operational funding through at least Q1 2024. Research and development expenses increased to $34.1 million in 2022, compounded by substantial general and administrative costs of $40.8 million. The company recorded a net loss of $58.2 million for the year. Overall, Senti is positioned for ongoing growth with its innovative Gene Circuit technology.